069269.0650 INFLAMMATORY DISORDER IN A FELIDAE CROSS-REFERENCE TO RELATED APPLICATIONS The present application claims priority to European Application No. 22202920.9, filed on October 21, 2022, the contents of which are hereby incorporated by reference in its entirety. SEQUENCE LISTING The instant application contains a Sequence Listings, which has been submitted in XML format via EFS-Web and is hereby incorporated by reference in its entirety. Said XML copy, created on September 29, 2023, is named 069269_0650_SL.xml and is 2,757 bytes in size. TECHNICAL FIELD The presently disclosed subject matter relates to the field of diagnosis and follow-up of an inflammatory disorder in a Felidae, in particular of a pet animal such as a cat. More particularly, the presently disclosed subject matter relates to the field of diagnosis and follow-up of Feline atopic syndrome (FAS), which includes Feline atopic skin syndrome (FASS), Flea allergy dermatitis (FAD), Feline food allergy (FFA), and associated conditions. The presently disclosed subject matter further relates to compounds, and compositions thereof, for treating an inflammatory disorder in a Felidae. BACKGROUND The complex intestinal microbiome is widely investigated in humans since the last fifty years. Studies have shown that the microbiome can be affected by different environmental factors and diseases, including systemic inflammatory diseases, with major or minor effects. In humans, long standing diseases such as obesity, inflammatory bowel diseases, allergic rhinitis, and atopic dermatitis are reportedly linked with the microbiome, in a controversial causal manner. Current studies focus in understanding its preventive role during infancy and bacterial strains involved in adults with allergic status. In particular, atopic dermatitis is a chronic inflammatory skin condition, starting in early childhood and is usually the first manifestation of the atopic march. Maturation of an ^{Active 106822693} 1 069269.0650 inappropriate T-helper type 2 (Th2) immune response that predominates at birth to a Th1 predominance in infancy and adulthood is conditional on the presence of commensal gut bacteria. The microbiome has a well-documented role in human atopic dermatitis, in particular the association of dysbiosis and an increase risk of atopy. American adults with allergies, especially to nuts and seasonal pollen, have low diversity, reduced Clostridiales, and increased Bacteroidales in their gut microbiota. This dysbiosis might be targeted to improve treatment or prevention of allergy (Hua et al; Allergy associations with the adult fecal microbiota: Analysis of the American Gut Project; EBioMedicine, 2016). Under certain conditions, it is hypothesized that this gut homeostasis condition is also disrupted in other non-human mammals. For example, dysbiosis may occur with a reduction of bacterial diversity, a loss of beneficial bacteria and an overgrowth of pathogens. Because microbial shifts are often noted with disease, it is thought that microbiome profiles may be used as biomarkers for diagnosis and/or monitoring in the future, as reported in the fecal microbiome of dogs (Lin et al.; An ambient temperature collection and stabilization strategy for canine microbiota studies; Nature, 2020). Inflammatory disorders, in particular those resulting from feline allergic diseases, are prevalent in cats (Halliwell et al.; Feline allergic diseases: introduction and proposed nomenclature; Veterinary Dermatology, 2021). Feline atopic skin syndrome (FASS) is an inflammatory and pruritic skin syndrome of cats manifested by a spectrum of reaction patterns, that may be associated with IgE antibodies to environmental allergens (Richard Halliwell; Immunopathogenesis of the feline atopic syndrome; Veterinary Dermatology, 2021). The cutaneous lesions of FASS are variable in appearance, and include miliary dermatitis (MD), self-inflicted alopecia/hypotrichosis (SIAH), head and neck pruritus (HNP) and eosinophilic granuloma complex (EGC) (Santoro et al.; Clinical signs and diagnosis of feline atopic syndrome: detailed guidelines for a correct diagnosis; Veterinary. Dermatology, 2021). In Felidae, the new consideration of gut microbiota role and the fast development of next-generation sequencing have also given access to these microbial data (Lyu et al.; Past, Present, and Future of Gastrointestinal Microbiota Research in Cats; Front. Microbiol., 2020). Similarly to other mammals, the vast majority of the gastrointestinal (GI) microbiota ^{Active 106822693} 2 069269.0650 in cats (over 99%) is composed of the predominant bacterial phyla Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria. One study has demonstrated a correlation between Feline Chronic Enteropathy severity and an increased Enterobacteriaceae (Simpson; Chapter 10 - The Role of the Microbiota in Feline Inflammatory Bowel Disease; August’s Consultations in Feline internal medicine, Vol.7, 2016). In one study, an increase of Bifidobacteriales and Lactobacilliacee was further associated with feline immunodeficiency virus infection (Weese et al.; The rectal microbiota of cats infected with feline immunodeficiency virus infection and uninfected controls; Veterinary Microbiology, 2015). There is thus a need for new biomarkers for detecting inflammatory disorders in Felidae; and particularly in cats. There is also a need for compounds and compositions for treating such inflammatory disorders in non-human mammals, including Felidae. The presently disclosed subject matter has a purpose to meet the above-mentioned needs. SUMMARY OF THE INVENTION A first main aspect of the presently disclosed subject matter relates to an in vitro method for the diagnosis or follow-up of an inflammatory disorder in a Felidae, comprising a step of determining the level of occurrence of Bacteroides vulgatus or Helicobacter canis in a digestive tract sample thereof; wherein: an increase of the level of Bacteroides vulgatus is indicative of the occurrence of the inflammatory disorder, a decrease of the level of Helicobacter canis is indicative of the occurrence of the inflammatory disorder, and/or an increase of the ratio level of Bacteroides vulgatus over Helicobacter canis, is/are indicative of the inflammatory disorder. In certain embodiments, the method comprises a step of determining the level of occurrence of Bacteroides vulgatus in the digestive tract sample thereof. In certain embodiments, the method comprises a step of determining the level of occurrence of Helicobacter canis in the digestive tract sample thereof. In certain embodiments, the method comprises a step of determining the level of occurrence of Bacteroides vulgatus and Helicobacter canis in the digestive tract sample thereof. ^{Active 106822693} 3 069269.0650 In certain embodiments, the inflammatory disorder is selected from a list consisting of: an allergic disorder, an inflammatory skin disorder, an inflammatory tract disorder, and a respiratory tract disorder. In certain embodiments, the inflammatory disorder is Feline atopic syndrome (FAS). In certain embodiments, the inflammatory disorder is selected from: Feline atopic skin syndrome (FASS), Flea allergy dermatitis (FAD), or Feline food allergy (FFA). In certain embodiments, the inflammatory disorder is Feline atopic skin syndrome (FASS). In certain embodiments, the inflammatory disorder is selected from: miliary dermatitis (MD), self-inflicted alopecia/hypotrichosis (SIAH), head and neck pruritus (HNP), eosinophilic granuloma complex (EGC). In certain embodiments, the digestive tract sample is selected from a list consisting of: a fecal sample, a gastric sample, a saliva sample, or fractions thereof; in particular a fecal sample, and fractions thereof. In certain embodiments, the Felidae is selected from a list consisting of: cheetah, puma, jaguar, leopard, lion, lynx, liger, tiger, panther, bobcat, ocelot, smilodon, caracal, serval and cats; in particular wild cats and domestic cats, including breeds and hybrids thereof; and most preferably domestic cats. In certain embodiments, the Felidae is selected from a list consisting of: Abyssinian, Aegean, American Bobtail, American Curl, American Ringtail, American Shorthair, American Wirehair, Aphrodite Giant, Arabian Mau, Asian, Asian Semi-longhair, Australian Mist, Balinese, Bambino, Bengal, Birman, Bombay, Brazilian Shorthair, British Longhair, British Shorthair, Burmese, Burmilla, California Spangled, Chantilly-Tiffany, Chartreux, Chausie, Colorpoint Shorthair, Cornish Rex, Cymric, Manx Longhair, Long-haired Manx, Cyprus, Devon Rex, Donskoy, Don Sphynx, Dragon Li, Chinese Li Hua, Dwelf, Egyptian Mau, European Shorthair, Exotic Shorthair, Foldex, German Rex, Havana Brown, Highlander, Himalayan, Colorpoint Persian, Japanese Bobtail, Javanese, Colorpoint Longhair, Kanaani, Khao Manee, Kinkalow, Korat, Korean Bobtail, Korn Ja, Kurilian Bobtail, Kuril Islands Bobtail, Lambkin, LaPerm, Lykoi, Maine Coon, Manx, Mekong Bobtail, Minskin, Minuet, Munchkin, Nebelung, Norwegian Forest Cat, Ocicat, Ojos Azules, Oregon Rex, Oriental Bicolor, Oriental Longhair, Oriental Shorthair, Persian, Peterbald, Pixie-bob, Ragamuffin, Liebling, Ragdoll, Raas, Russian Blue, Russian White, Russian Black, Russian Tabby, Sam Sawet, Savannah, Scottish Fold, Selkirk Rex, Serengeti, ^{Active 106822693} 4 069269.0650 Serrade Petit, Siamese, Siberian, Siberian Forest Cat, Neva Masquerade, Singapura, Snowshoe, Sokoke, Somali, Sphynx, Suphalak, Thai, Thai Lilac,Thai Blue Point, Thai Lilac Point, Tonkinese, Toybob, Toyger, Turkish Angora, Turkish Van, Turkish Vankedisi, Ukrainian Levkoy, and York Chocolate. In certain embodiments, the step of determining the level of occurrence of Bacteroides vulgatus or Helicobacter canis comprises detecting, preferably quantifying, all or part of a nucleic acid sequence of said Bacteroides vulgatus or Helicobacter canis. A second main aspect of the presently disclosed subject matter relates to a compound, or composition thereof, selected from the list consisting of: a corticosteroid, in particular a glucocorticoid or a mineralocorticosteroid; ciclosporin; oclatinib; H1-receptor blocking antihistamine; essential fatty acid selected from the group consisting of: linoleic acid, linolenic acid and arachidonic acid; palmitoylethanolamide (PEA); and combinations thereof; for use in a method for treating an inflammatory disorder in a Felidae, said Felidae being characterized by: an increased level of Bacteroides vulgatus in the digestive tract, a decreased level of Helicobacter canis in the digestive tract, and/or an increased ratio level of Bacteroides vulgatus over Helicobacter canis in the digestive tract. DETAILED DESCRIPTION Bacteria species Bacteroides vulgatus and Helicobacter canis are known to be present in the gut microbiota of Felidae, domestic cats. However, the present disclosure is the first to report that those two species exhibit a difference in prevalence, namely Bacteroides vulgatus and Helicobacter canis, in a group of cats with feline atopic skin syndrome (FASS). This modulation was unexpected, due to the lack of studies on the relationship between the gut microbiota and inflammatory disorders, such as FASS, in Felidae. Accordingly, the present disclosure reports: - an increase of the level of Bacteroides vulgatus (e.g., over a reference value, for example healthy individuals), which is indicative of the occurrence of the inflammatory disorder, and/or - a decrease of the level of Helicobacter canis (e.g., below a reference value, for example healthy individuals), which is indicative of the occurrence of the inflammatory disorder, and/or ^{Active 106822693} 5 069269.0650 - an increase of the ratio level of Bacteroides vulgatus over Helicobacter canis (e.g., when compared to a healthy individual or to the same individual in a previous/healthier condition), which is/are indicative of the occurrence of the inflammatory disorder. In particular, the modulation of Helicobacter canis, which is less preponderant in the FASS group, is unexpected because this bacterial strain was previously described in both diarrheic and healthy patients in other studies, including Foley et al. (Isolation of Helicobacteri canis from a Colony of bengal Cats with Endemic Diarrhea; Journal of Clinical Microbiology; 1999) and Stanley et al. (Helicobacter canis sp. nov., a new species from dogs: an integrated study of phenotype and genotype; J. Gen. Microbiol.1993). Without wishing to be bound by the theory, the present disclosure demonstrates that the above-mentioned modulations constitute a novel biomarker of inflammatory disorders in Felidae, including their associated symptoms with Feline atopic syndrome (FAS) and feline atopic skin syndrome (FASS). The present disclosure further discloses compounds and compositions, for treating inflammatory disorders toward sub-populations of Felidae, characterized by: - an increase of the level of Bacteroides vulgatus over a reference value, and/or - a decrease of the level of Helicobacter canis below a reference value, and/or - an increase of the ratio level of Bacteroides vulgatus over Helicobacter canis. In particular, the present disclosure further discloses compounds and compositions, for treating inflammatory disorders toward sub-populations of Felidae, characterized by: - an increase of the level of Bacteroides vulgatus over a reference value, and/or - a decrease of the level of Helicobacter canis below a reference value, and/or - an increase of the ratio level of Bacteroides vulgatus over Helicobacter canis. More particularly, the present disclosure discloses such compounds and compositions, previously reported as efficient toward the treatment of an allergic disorder, an inflammatory skin disorder, an inflammatory tract disorder, and/or a respiratory tract disorder, and preferably of a Feline Atopic Syndrome (FAS), which is considered as particularly relevant for the identified sub-population(s) of Felidae. The present disclosure further discloses a method for treating an inflammatory disorder in a Felidae, comprising the steps of: a) determining an increased level of Bacteroides vulgatus in the digestive tract, a decreased level of Helicobacter canis in the digestive tract, and/or an increased ratio level of Bacteroides vulgatus over Helicobacter ^{Active 106822693} 6 069269.0650 canis in the digestive tract of the felidae, in particular in a digestive tract sample of the felidae; and b) administering to the felidae at least one compound or composition selected from a corticosteroid, in particular a glucocorticoid or a mineralocorticosteroid, ciclosporin, oclatinib,H1-receptor blocking antihistamine, essential fatty acid selected from the group consisting of linoleic acid, linolenic acid and arachidonic acid, palmitoylethanolamide (PEAum), and/or combinations thereof. For clarity and not by way of limitation, the detailed description of the presently disclosed subject matter is divided into the following subsections: 1. Definitions; and 2. Diagnostic methods. 1. Definitions The terms used in this specification generally have their ordinary meanings in the art, within the context of this disclosure and in the specific context where each term is used. Certain terms are discussed below, or elsewhere in the specification, to provide additional guidance in describing the compositions and methods of the disclosure and how to make and use them. The following definitions are provided for the present specification, including the claims. As used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a compound” includes mixtures of compounds. As used herein, the terms “include”, “including”, “comprise,” “comprising,” or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but can include other elements not expressly listed or inherent to such process, method, article, or apparatus. In the detailed description herein, references to “embodiment,” “an embodiment,” “one embodiment,” “in various embodiments,” etc., indicate that the embodiment(s) described can include a particular feature, structure, or characteristic, but every embodiment might not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it is submitted that it is within the knowledge of one skilled in the art to affect such feature, ^{Active 106822693} 7 069269.0650 structure, or characteristic in connection with other embodiments whether or not explicitly described. After reading the description, it will be apparent to one skilled in the relevant art(s) how to implement the disclosure in alternative embodiments. As used herein, the term “about” or “approximately”, as used herein, means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 3 or more than 3 standard deviations, per the practice in the art. Alternatively, “about” can mean a range of up to 10%, more preferably up to 5%, and more preferably still up to 1% of a given value. As used herein, the terms “treat” or “treatment” in the present text refers to the administration or consumption of a composition according to the disclosure with the purpose to cure, heal, alleviate, relieve, reduce, alter, remedy, ameliorate, improve, or affect a disorder according to the disclosure, the symptoms of the condition, or to prevent or delay the onset of the symptoms, complications, or otherwise arrest or inhibit further development of the disorder in a statistically significant manner. As used herein, the term “inflammatory disease” is meant to refer to any disease/disorder associated with inflammation, without restrictions, including those associated with one selected from an allergic (or atopic) disorder, an inflammatory skin disorder, an inflammatory digestive tract disorder, and a respiratory tract disorder. For example, the term can encompass one or more of the following conditions and syndromes: an atopic disease, Feline Atopic Syndrome (FAS), Feline Atopic Skin Syndrome (FASS), Feline asthma, Feline food allergy (FFA). The term further encompasses allergic dermatitis, allergic enteritis and asthma. As used herein, the term “atopy” or “atopic disease” is meant to refer to the commonly acknowledged definition, without restrictions. The essential features of an atopic disease are defined as a predisposition to allergic disease affecting the skin. Hence, the term encompasses any clinical dermatitis hypersensitivity associated with an inherited tendency to produce immunoglobulin E (IgE) antibodies in response to environmental proteins such as pollen, house dust mite, and food allergens. As used herein, the term “Feline Atopic Syndrome” or “FAS” is meant to encompass allergic diseases of the skin, gastrointestinal tract and respiratory tract, in the broadest sense, ^{Active 106822693} 8 069269.0650 as described in Halliwell et al. (Feline allergic diseases: introduction and proposed nomenclature; Veterinary Dermatology, 2021). Hence, the term encompasses allergic dermatitis associated with environmental allergen, food allergy and asthma that can be associated with IgE antibodies. Accordingly, the term encompasses those inflammatory diseases selected from Feline atopic skin syndrome (FASS), Flea allergy dermatitis (FAD), Feline food allergy (FFA) and Feline asthma. As used herein, the term “Feline Atopic Skin Syndrome” or “FASS” is meant to refer to the commonly acknowledged definition, without restrictions. Hence, the term encompasses allergic skin diseases, associated with environmental allergies. More particularly, it can encompass one or more of the following conditions: miliary dermatitis (MD), self-inflicted alopecia/hypotrichosis (SIAH), head and neck pruritus (HNP), eosinophilic granuloma complex (EGC). In particular, FASS is commonly associated with an inflammatory and pruritic skin syndrome (e.g., found in cats). Food allergy and flea allergy can both contribute to the syndrome. As used herein, the term “Feline asthma” is meant to refer to the commonly acknowledged definition, without restrictions. Hence, the term encompasses an eosinophilic inflammatory disease affecting the bronchioles and leading to spontaneous reversible bronchoconstriction and airway remodelling, manifested by acute respiratory distress or chronic coughing and expiratory wheezing, that can be associated with IgE antibodies to inhaled allergens. As used herein, the term “Feline food allergy” is meant to refer to the commonly acknowledged definition, without restrictions. Hence, the term encompasses the clinical manifestations, including those of FASS, that are attributable to the allergen-specific reactivity to an ingested food item. As used herein, the term “corticosteroid” is meant to refer to any corticosteroid hormone without restrictions, including naturally occurring corticosteroids and synthetic corticosteroids. Hence, the term encompasses, in particular, a glucocorticoid or a mineralocorticosteroid, without limitation to a particular administration route. Hence, the term encompasses topical, inhaled and system corticosteroids (e.g., glucocorticoids) in the absence of indication of the contrary. As used herein, the term “glucocorticoid” is meant to refer to a steroid capable of binding to the glucocorticoid receptor without restrictions. Such compounds encompass to, ^{Active 106822693} 9 069269.0650 but are not limited to, dexamethasone, dexamethasone containing agents, cortivazol, hydrocortisone, methylprednisolone, paramethasone, prednisone, prednisolone, prednylidene, cortisone, budesonide, betamethasone, beclomethasone, mometasone furoate, fluticasone, flunisolide, Triamcinolone Acetonide, methylprednisone, derivatives and salts thereof. Other particular examples of glucocorticoids include dexamethasone base, dexamethasone sodium phosphate, dexamethasone hemi succinate, dexamethasone sodium succinate, dexamethasone succinate, and dexamethasone acetate. As used herein, the term “ciclosporin”, “cyclosporine,” “cyclosporin,” or “cyclosporin A” is meant to refer to the compound referenced under CAS number 59865- 13-3, and salts thereof; which thus can include microemulsion and liquid forms thereof. As used herein, the term “oclatinib” is meant to refer to the compound referenced under CAS number 1208319-26-9, and salts thereof. As used herein, the term “ H1-receptor blocking antihistamine ,” “H1 antagonist” or “H1 blocker” is meant to refer to a compound capable of blocking the action of histamine at the H1 receptor, which can thus encompass H1-antihistamines, including those selected from Loratidine, Cetirizine, Cyporheptadine, Chlorpheniramine, Clemastine, and salts thereof. As used herein, the term “essential fatty acid” refers to those fatty acids which are considered as essential in Felidae (e.g., cats), so termed because they cannot be synthesized from non-fat sources such as carbohydrate or protein. Essential fatty acids in Felidae (e.g., cats) comprise linoleic acid, linolenic acid and arachidonic acid. As used herein, the term “feline” or “Felidae” refers to an animal that is a member of the family Felidae; including without limitation the subfamilies, Felinae, Pantherinae, and Acinonychinae; the genera Caracal, Catopuma, Felis, Herpailurus, Leopardus, Leptailurus, Lynx, Oncifelis, Oreailurus, Otocolobus, Prionailurus, Profelis, Puma, Neofelis, Panthera, Pardofelis, and Uncia; the species felis, lybica, jubatus, caracal, badia, bieti, chaus, margarita, nigripes, silvestris, gordonii, yaguarondi, pardalis, tigrinus, wiedi, serval, canadensis, lynx, pardinus, rufus, colocolo, geoffroyi, guigna, jacobita, manul, bengalensis, planiceps, rubiginosus, viverrinus, aurata, concolor, nebulosa, leo, onca, pardus, tigris, marmorata, and uncial. The term can thus include animals, for example companion (or “pet”) animals, selected from, without limitation, cheetah, puma, jaguar, leopard, lion, lynx, liger, tiger, panther, bobcat, ocelot, smilodon, caracal, serval and cats. As used herein, cats encompass wild cats and domestic cats, and most preferably domestic cats. ^{Active 106822693} 10 069269.0650 The present disclosure relates, in particular, to domestic cat breed. Domestic cat breeds which are particularly considered, in the context of the present disclosure, can comprise or consist of those recognized by the International Cat Association (TICA). Examples of cat breeds which are considered herein include those selected from the list consisting of: Abyssinian, Aegean, American Bobtail, American Curl, American Ringtail, American Shorthair, American Wirehair, Aphrodite Giant, Arabian Mau, Asian, Asian Semi-longhair, Australian Mist, Balinese, Bambino, Bengal, Birman, Bombay, Brazilian Shorthair, British Longhair, British Shorthair, Burmese, Burmilla, California Spangled, Chantilly-Tiffany, Chartreux, Chausie, Colorpoint Shorthair, Cornish Rex, Cymric, Manx Longhair, Long-haired Manx, Cyprus, Devon Rex, Donskoy, Don Sphynx, Dragon Li, Chinese Li Hua, Dwelf, Egyptian Mau, European Shorthair, Exotic Shorthair, Foldex, German Rex, Havana Brown, Highlander, Himalayan, Colorpoint Persian, Japanese Bobtail, Javanese, Colorpoint Longhair, Kanaani, Khao Manee, Kinkalow, Korat, Korean Bobtail, Korn Ja, Kurilian Bobtail, Kuril Islands Bobtail, Lambkin, LaPerm, Lykoi, Maine Coon, Manx, Mekong Bobtail, Minskin, Minuet, Munchkin, Nebelung, Norwegian Forest Cat, Ocicat, Ojos Azules, Oregon Rex, Oriental Bicolor, Oriental Longhair, Oriental Shorthair, Persian, Peterbald, Pixie-bob, Ragamuffin, Liebling, Ragdoll, Raas, Russian Blue, Russian White, Russian Black, Russian Tabby, Sam Sawet, Savannah, Scottish Fold, Selkirk Rex, Serengeti, Serrade Petit, Siamese, Siberian, Siberian Forest Cat, Neva Masquerade, Singapura, Snowshoe, Sokoke, Somali, Sphynx, Suphalak, Thai, Thai Lilac,Thai Blue Point, Thai Lilac Point, Tonkinese, Toybob, Toyger, Turkish Angora, Turkish Van, Turkish Vankedisi, Ukrainian Levkoy, York Chocolate. As used herein, the term “food product” or “food composition” or “diet” or “foodstuff” can refer to, for example, without limitation foodstuff, diet, food supplement, liquid and/or a material that can contain proteins, carbohydrates and/or crude fats. For example, the term can also refer to supplementary substances or additives, for example, minerals, vitamins, and condiments (See Merriam-Webster’s Collegiate Dictionary, 10th Edition, 1993). Such food compositions or products can be nutritionally complete or not. As used herein, the term “gastrointestinal sample” can refer to any sample, or fraction thereof, which is susceptible to be derived from the gastrointestinal tract, including the digestive tract as a whole, from the mouth to the anus, which can thus include the higher gastrointestinal tract, the lower gastrointestinal tract, and combinations thereof; which can ^{Active 106822693} 11 069269.0650 thus include any biological sample or fraction thereof, derived from the mouth, the stomach, the small intestine, the colon, the cecum, the rectum or the anus. A gastrointestinal sample according to the present disclosure can thus comprise, or consist of, a gastric, colorectal, duodenal or rectal sample, or fractions thereof. As used herein, the terms “fecal sample,” ”stool sample,” and “feces” can be used interchangeably. A suitable nucleic acid sample, for example a suitable nucleic acid gastrointestinal sample, can thus comprise, or consist of, a nucleic acid sample obtained from a fecal sample, or fractions thereof. Fecal samples are commonly used in the art to sample gut microbiota. A preferred nucleic acid sample can be a nucleic acid sample obtained from a suitable fecal sample. Methods for obtaining a fecal sample from a subject are known in the art and include, but are not limited to, rectal swab, stool collection, and sampling of the floor or environment where animals defecate (e.g., a pen in a commercial animal farm). Suitable fecal samples can be freshly obtained or can have been stored under appropriate temperatures and conditions known in the art. As used herein, the term “gastrointestinal sample” can thus encompass a nucleic acid sample (e.g., a nucleic acid fecal sample) which comprises one or more (a plurality of) heterogeneous nucleic acids produced by a subject’s gut microbiota. A gastrointestinal sample according to the present disclosure can comprise, or consist of, a stool sample or fractions thereof. Suitable gastrointestinal samples for interrogation using the methods of the application include but are not limited to samples of gut contents and/or mucosal biopsies obtained directly by an invasive technique, e.g., by surgery, by rectal or intestinal sampling via colonoscopy-type procedures, or by other means. Most preferably, samples are obtained by less invasive methods, e.g., stool samples. Methods for extracting nucleic acids from a gastrointestinal sample (e.g., a fecal/stool sample) are also well known in the art. The nucleic acids comprising the nucleic acid sample may or may not be amplified prior to being used as an input, depending upon the type and sensitivity of the data acquisition component. When amplification is desired, nucleic acids can be amplified via polymerase chain reaction (PCR) from a nucleic acid sample. Methods for performing PCR are well known in the art. Selection of nucleic acids or regions of nucleic ^{Active 106822693} 12 069269.0650 acids to amplify are discussed above. The nucleic acids comprising the nucleic acid sample can also be fluorescently or chemically labeled, fragmented, or otherwise modified prior to sequencing or hybridization to an array as is routinely performed in the art. As used herein, the term “microbiome” refers to the collection of genomes from all microorganisms, including bacterial, viruses and fungi; in particular to the totality of bacteria, their genetic elements (genomes) in a defined environment, e.g., within the gut of a host, the latter then being referred to as the “gut microbiome”. A gut microbiome profile can thus represent the presence, absence or the abundance of one or more of bacterial taxa identified in the gut biological sample; bacterial metabolic products in said gut biological sample; proteins in said gut biological sample; nucleic acids in said gut biological sample. Microbial taxa can be defined at any taxonomic level, including phyla, class, order, family, genus, species, strain, or a combination thereof. A skilled artisan will appreciate that while more resolved levels of taxonomy (e.g., genus, species or strain) can generally be more predictive, there can be circumstances where use of higher levels of taxonomy improves the performance of the system. According to the present disclosure, the said bacteria, bacterial metabolic products and said proteins and/or said nucleic acids are derived from Helicobacter canis and/or Bacteroides vulgatus. According to some preferred embodiments, the gut microbiome profile can be determined based on an analysis of amplification products of nucleic acids, in particular of DNA and/or RNA of the gut microbiota, e.g., based on an analysis of amplification products of genes coding for one or more of small subunit rRNA, etc. and/or based on an analysis of proteins and/or metabolic products present in the biological sample (e.g., the gastrointestinal sample). Gut microbiome profiles can be “compared” by any of a variety of statistical analytic procedures. As used herein, the term “Operational taxonomic unit” (“OTU”, plural “OTUs”) refers to a terminal leaf in a phylogenetic tree and is defined by a specific genetic sequence and all sequences that share sequence identity to this sequence at the level of species. A “type” or a plurality of “types” of bacteria includes an OTU or a plurality of different OTUs, and also encompasses a strain, species, genus, family or order of bacteria. The specific genetic sequence can be the 16S rRNA sequence or a portion of the 16S rRNA sequence or it can be a functionally conserved housekeeping gene found broadly across the eubacterial kingdom. OTUs typically share at least 95%, 96%, 97%, 98%, or 99% sequence identity; ^{Active 106822693} 13 069269.0650 preferably at least 97% sequence identity. OTUs are frequently defined by comparing sequences between organisms. Sequences with less than 95% sequence identity are generally not considered to form part of the same OTU. As used herein, a “16S rRNA” can be either the 16S rRNA as such or the genomic sequence from which originates the corresponding 16S rRNA. A 16S rRNA can be sequenced by using primers/probes targeting the V3-V4 hypervariable region, such as DNA or RNA probes, for example DNA probes of sequence SEQ ID NO: 1 and SEQ ID NO: 2. A suitable nucleic acid used for taxonomic classification is universally distributed among the gut microbial population being queried allowing for the analysis. According to some embodiments, the nucleic acid has both a conserved region and at least one region subject to variation. The presence of at least one variable region allows sufficient diversification to provide a tool for classification, while the presence of conserved regions enables the design of suitable primers for amplification (if needed) and/or probes for hybridization for various taxa at different taxonomic levels ranging from individual strains to whole phyla. While any suitable nucleic acid known in the art can be used, one skilled in the art will appreciate that selection of a nucleic acid or region of a nucleic acid to amplify can differ by environment. In some embodiments, a nucleic acid queried is a small subunit ribosomal RNA gene. For bacterial populations, the V regions of the 16s rRNA gene, in particular the V3 and/or V4 regions of the 16s rRNA gene are suitable, though other suitable regions are known in the art. Guidance for selecting a suitable 16S rRNA region to amplify can be found throughout the art, including Guo F et al., PLOS One 8(10) e76185, 2013; Soergel DAW et al., ISME Journal 6: 1440, 2012; and Hamady M et al., Genome Res.19: 1 141, 2009. For example, a 16S rRNA of the disclosure can be a partial 16S rRNA nucleic acid sequence or a full length 16S rRNA nucleic acid sequence. When the determination of a level of bacteria (e.g., helicobacter canis and/or bacteroides vulgatus) is achieved through determination of a nucleic acid, for example of DNA and/or RNA from the one or more gut microbiota, it is preferably achieved through determination of one or more regions, in particular V regions, of the 16S rRNA from said one or more bacteria, and/or the determination of one or more OTUs from the said bacteria. Suitable nucleic acids used for classification can include a nucleic acid that encodes a polypeptide which can be assigned to a functional group known in the art. The current technology is not limited to any one classification scheme ^{Active 106822693} 14 069269.0650 As used herein, the “percentage identity” or “sequence identity” between two sequences of proteins or nucleic acids (depending on what is applicable) means the percentage of identical amino acid or base, e.g., nucleotides or nucleosides, residues between the two sequences to be compared, obtained after optimal alignment, this percentage being purely statistical and the differences between the two sequences being distributed randomly along their length. The comparison of sequences is traditionally carried out by comparing the sequences after having optimally aligned them, said comparison being able to be conducted by segment or by using an “alignment window”. Optimal alignment of the sequences for comparison can be carried out, in addition to comparison by hand, by means of the local homology algorithm of Smith and Waterman (1981), by means of the local homology algorithm of Neddleman and Wunsch (1970), by means of the similarity search method of Pearson and Lipman (1988) or by means of computer software using these algorithms (GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI, or by the comparison software BLAST NR or BLAST P). The percentage identity between two sequences is determined by comparing the two optimally-aligned sequences in which the sequence to compare can have additions or deletions compared to the reference sequence for optimal alignment between the two sequences. Percentage identity is calculated by determining the number of positions at which the amino acid residue is identical between the two sequences, preferably between the two complete sequences, dividing the number of identical positions by the total number of positions in the alignment window and multiplying the result by 100 to obtain the percentage identity between the two sequences. After a sample is obtained, the types and/or the quantity (e.g., occurrence or abundance) in the sample of at least one bacteria of interest (e.g., Helicobacter canis and/or Bacteroides vulgatus) is determined according to any method known to those of skill in the art. In addition, a total amount of bacteria can be determined, and then for each constituent bacteria, a fractional percentage (e.g., relative amount, ratio, distribution, frequency, percentage, etc.) of the total is calculated. The result is typically correlated with at least one suitable control result, e.g., control results of the same parameter(s) obtained from asymptomatic individuals/Felidae (negative control), and/or individuals/Felidae known to have an inflammatory disorder of interests (positive control), or from individuals/Felidae ^{Active 106822693} 15 069269.0650 who have had the inflammatory disorder of interest and are being or have been treated, either successfully or unsuccessfully. As used herein, a modulation of the level of Bacteroides vulgatus or Helicobacter canis for a given subject/individual is determined based on a reference value; which can correspond to an increase or a decrease based on said reference value. As used herein, “an increase of the level of Bacteroides vulgatus” or “an increase of the level of Helicobacter canis” over a reference value can encompass any statistically significant increase over said reference value. It will be readily understood herein that the level of increase will thus be necessarily dependent upon the method of detection and of the reference value which is considered. For example, an increase of the level of a reference value can thus be of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100% higher or at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold higher, at least 6-fold higher, at least 7-fold higher, at least 8-fold higher, at least 9-fold higher, at least 10-fold higher, at least 100-fold higher than said reference value. As used herein, “a decrease of the level of Bacteroides vulgatus” or “a decrease of the level of Helicobacter canis” below a reference value can encompass any statistically significant increase below said reference value. It will be readily understood herein that the level of decrease will thus be necessarily dependent upon the method of detection and of the reference value which is considered. For example, a decrease of the level of a reference value can thus be of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100% lower or at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9- fold, and at least 10-fold lower, at least 100-fold lower than said reference value. 2. Diagnostic methods According to a first main embodiment, the presently disclosed subject matter thus relates to an in vitro method for the diagnosis or follow-up of an inflammatory disorder in a Felidae, comprising a step of determining the level of occurrence of Bacteroides vulgatus or Helicobacter canis in a digestive tract sample thereof, wherein: - an increase of the level of Bacteroides vulgatus is indicative of the occurrence of the inflammatory disorder, and/or ^{Active 106822693} 16 069269.0650 - a decrease of the level of Helicobacter canis is indicative of the occurrence of the inflammatory disorder, and/or - an increase of the ratio level of Bacteroides vulgatus over Helicobacter canis, is/are indicative of the inflammatory disorder. According to a particular embodiment, the in vitro method comprises a step of determining the level of occurrence of Bacteroides vulgatus in the digestive tract sample thereof. According to a particular embodiment, the in vitro method comprises a step of determining the level of occurrence of Helicobacter canis in the digestive tract sample thereof. According to a particular embodiment, the in vitro method comprises a step of determining the level of occurrence of Bacteroides vulgatus and Helicobacter canis in the digestive tract sample thereof. According to a particular embodiment of the in vitro method, the inflammatory disorder is selected from a list consisting of an allergic disorder, an inflammatory skin disorder, an inflammatory digestive tract disorder, and a respiratory tract disorder. According to a particular embodiment of the in vitro method, the inflammatory disorder is Feline atopic syndrome (FAS). According to a particular embodiment of the in vitro method, the inflammatory disorder is selected from Feline atopic skin syndrome (FASS), Flea allergy dermatitis (FAD), Feline food allergy (FFA). According to a particular embodiment of the in vitro method, the inflammatory disorder is Feline atopic skin syndrome (FASS). According to a particular embodiment of the in vitro method, the inflammatory disorder is selected from miliary dermatitis (MD), self-inflicted alopecia/hypotrichosis (SIAH), head and neck pruritus (HNP), eosinophilic granuloma complex (EGC). According to a particular embodiment of the in vitro method, the digestive tract sample is selected from a list consisting of a fecal sample, a gastric sample, a saliva sample, or fractions thereof; in particular a fecal sample or fractions thereof. According to a particular embodiment of the in vitro method, the Felidae is selected from a list consisting of cheetah, puma, jaguar, leopard, lion, lynx, liger, tiger, panther, ^{Active 106822693} 17 069269.0650 bobcat, ocelot, smilodon, caracal, serval and cats; in particular wild cats and domestic cats, including breeds and hybrids thereof; and most preferably domestic cats. According to a particular embodiment of the in vitro method, the Felidae is selected from a list consisting of: Abyssinian, Aegean, American Bobtail, American Curl, American Ringtail, American Shorthair, American Wirehair, Aphrodite Giant, Arabian Mau, Asian, Asian Semi-longhair, Australian Mist, Balinese, Bambino, Bengal, Birman, Bombay, Brazilian Shorthair, British Longhair, British Shorthair, Burmese, Burmilla, California Spangled, Chantilly-Tiffany, Chartreux, Chausie, Colorpoint Shorthair, Cornish Rex, Cymric, Manx Longhair, Long-haired Manx, Cyprus, Devon Rex, Donskoy, Don Sphynx, Dragon Li, Chinese Li Hua, Dwelf, Egyptian Mau, European Shorthair, Exotic Shorthair, Foldex, German Rex, Havana Brown, Highlander, Himalayan, Colorpoint Persian, Japanese Bobtail, Javanese, Colorpoint Longhair, Kanaani, Khao Manee, Kinkalow, Korat, Korean Bobtail, Korn Ja, Kurilian Bobtail, Kuril Islands Bobtail, Lambkin, LaPerm, Lykoi, Maine Coon, Manx, Mekong Bobtail, Minskin, Minuet, Munchkin, Nebelung, Norwegian Forest Cat, Ocicat, Ojos Azules, Oregon Rex, Oriental Bicolor, Oriental Longhair, Oriental Shorthair, Persian, Peterbald, Pixie-bob, Ragamuffin, Liebling, Ragdoll, Raas, Russian Blue, Russian White, Russian Black, Russian Tabby, Sam Sawet, Savannah, Scottish Fold, Selkirk Rex, Serengeti, Serrade Petit, Siamese, Siberian, Siberian Forest Cat, Neva Masquerade, Singapura, Snowshoe, Sokoke, Somali, Sphynx, Suphalak, Thai, Thai Lilac,Thai Blue Point, Thai Lilac Point, Tonkinese, Toybob, Toyger, Turkish Angora, Turkish Van, Turkish Vankedisi, Ukrainian Levkoy, York Chocolate. According to a particular embodiment, the in vitro method comprises a step of determining the level of occurrence of Bacteroides vulgatus or Helicobacter canis comprising determining, preferably quantifying, all or part of a nucleic acid sequence of said Bacteroides vulgatus or Helicobacter canis. According to some particular embodiments of the in vitro method for the diagnosis or follow-up of an inflammatory disorder, the method comprises a step of contacting a digestive tract sample, or a fraction thereof, e.g., a feces/stool sample, with one or more probes capable of specifically hybridizing to one or more gut microbiome nucleic acid sequences, in particular Bacteroides vulgatus and/or Helicobacter canis. According to some particular embodiments of the in vitro method for the diagnosis or follow-up of an inflammatory disorder, the method comprises a step of detecting and/or ^{Active 106822693} 18 069269.0650 isolating the probes that specifically hybridize to gut microbiome nucleic acid sequences within the sample. According to some particular embodiments of the in vitro method for the diagnosis or follow-up of an inflammatory disorder, the method comprises a step of sequencing gut microbiome nucleic acid sequences which are susceptible to be present in the digestive tract sample. According to some particular embodiments of the in vitro method for the diagnosis or follow-up of an inflammatory disorder, the method comprises a step of comparing gut microbiome nucleic acid sequences with a database comprising reference gut microbiome nucleic acid sequences, in particular reference gut microbiome nucleic acid sequences from Bacteroides vulgatus and/or Helicobacter canis. According to some particular embodiments of the in vitro method for the diagnosis or follow-up of an inflammatory disorder, the method comprises the following steps: a) contacting a digestive tract sample, or a fraction thereof, with one or more probes capable of specifically hybridizing to one or more gut microbiome nucleic acid sequences, in particular Bacteroides vulgatus and/or Helicobacter canis; b) optionally detecting and/or isolating the probes that specifically hybridize to gut microbiome nucleic acid sequences within the sample; c) sequencing the gut microbiome nucleic acid sequences hybridized to the one or more probes; and d) comparing the sequences from (c) with a database comprising reference gut microbiome nucleic acid sequences, in particular reference gut microbiome nucleic acid sequences from Bacteroides vulgatus and/or Helicobacter canis, in order to determine the identity of the hybridized gut microbiome nucleic acid in the sample. 3. Compounds, compositions and methods for treatment According to a second main embodiment, the presently disclosed subject matter relates to a compound, or composition thereof, for example a food composition, for use in a method for treating an inflammatory disorder in a Felidae, said Felidae being characterized by: an increased level of Bacteroides vulgatus in the digestive tract, a decreased level of Helicobacter canis in the digestive tract, and/or an increased ratio level of Bacteroides vulgatus over Helicobacter canis in the digestive tract. ^{Active 106822693} 19 069269.0650 According to said second main embodiment, the presently disclosed subject matter relates to a compound, or composition thereof, selected from the list consisting of: - a corticosteroid, in particular a glucocorticoid or a mineralocorticosteroid; - ciclosporin; - oclatinib; - H1-receptor blocking antihistamine; - essential fatty acid selected from the group consisting of linoleic acid, linolenic acid and arachidonic acid; - palmitoylethanolamide (PEA), for example ultra-micronized PEA; - and combinations thereof; for use in a method for treating an inflammatory disorder in a Felidae, said Felidae being characterized by: an increased level of Bacteroides vulgatus in the digestive tract, a decreased level of Helicobacter canis in the digestive tract, and/or an increased ratio level of Bacteroides vulgatus over Helicobacter canis in the digestive tract. According to particular embodiments, the compound, or composition thereof, for use according to the present disclosure, is a food composition, which may or may not be nutritionally complete; for example a food additive. According to particular embodiments, the compound, or composition thereof, for use according to the present disclosure, is for use in a method for treating an inflammatory disorder in a Felidae, said inflammatory disorder being Feline atopic skin syndrome (FASS). The presently disclosed subject matter also relates to a method for treating an inflammatory disorder in a Felidae, said Felidae being characterized by: an increased level of Bacteroides vulgatus in the digestive tract, a decreased level of Helicobacter canis in the digestive tract, and/or an increased ratio level of Bacteroides vulgatus over Helicobacter canis in the digestive tract. The presently disclosed subject matter also related to a method for treating an inflammatory disorder in the Felidae, comprising the step of administering to the felidae at least one compound or composition selected from a corticosteroid, in particular a glucocorticoid or a mineralocorticosteroid, ciclosporin, oclatinib, H1-receptor blocking antihistamine, essential fatty acid selected from the group consisting of linoleic acid, linolenic acid and arachidonic acid, palmitoylethanolamide (PEA), and/or combinations thereof. ^{Active 106822693} 20 069269.0650 The presently disclosed subject matter also relates to a method for treating an inflammatory disorder in a Felidae, comprising the steps of: a) determining an increased level of Bacteroides vulgatus in the digestive tract, a decreased level of Helicobacter canis in the digestive tract, and/or an increased ratio level of Bacteroides vulgatus over Helicobacter canis in the digestive tract of the felidae, in particular in a digestive tract sample of the felidae; and b) administering to the felidae at least one compound or composition selected from a corticosteroid, in particular a glucocorticoid or a mineralocorticosteroid, ciclosporin, oclatinib,H1-receptor blocking antihistamine, essential fatty acid selected from the group consisting of linoleic acid, linolenic acid and arachidonic acid, palmitoylethanolamide (PEAum), and/or combinations thereof. EXAMPLES The present disclosure is further illustrated by, without in any way being limited to, the examples below. EXAMPLE 1 Material & Methods Study population Animals were recruited in France by four ECVD veterinarians and three (Fr)CertAVP(VD) veterinarians. Twenty feline referral cases presented to the clinic with a feline atopic skin syndrome were enrolled. Clinical signs were consistent with miliary dermatitis (MD) and/or self-inflicted alopecia/hypotrichosis (SIAH) and/or head and neck pruritus (HNP) and/or eosinophilic granuloma complex (EGC). To be included in the study, the patient must have been more than 9 months and less than 12 years old, controlled with appropriate external antiparasitic treatment against flea and dewormed. No visible and cytologic signs suggestive of active bacterial and yeast infection were accepted. No diarrhea was also required, and no drug intake is tolerated within the last 14 days previous to consultation and sampling. Twenty one healthy cats were recruited for the control group. These cats belonged to the same range of age and were up to date with the usual regular antiparasitic treatments. Their status was free of any clinical sign of disease and are neither suffering of any systemic chronic disease nor receiving any drug. Cats with any signs of skin disease were excluded from the recruitment. Sample collection and DNA extraction ^{Active 106822693} 21 069269.0650 Samples were collected from FASS and healthy cats using a sterile swab provided along with a clear tube (Isohelix DAN buccal Swabs, Harrietsham, Kent, UK, reference SK- 1S). Each swab was pre-moistened with sterile normal saline solution before being softly introduced into the rectum until the entire collection part disappeared through the anus. The swab was then rotated ten times before being withdrawn. Each swab extremity was stored in a sterile Eppendorf tube and labelled with permanent marker. The tube was frozen at -20°C and kept at the clinic until shipment to a -80°C storage before analysis. The rectal swabs were extracted with the Macherey Nagel Soil Kit using the combination of Lysis Buffer SL1 and Enhancer SX. DNA quantity and quality was assessed before analyzing, and stored at -20°C. Amplification and sequencing In order to assess the bacterial microbiota, two bacterial analysis were performed. The Axiom Microbiome Array, using Applied Biosystems™ Axiom™ assay biochemistry, interrogates nonpolymorphic sequences in both family-conserved and target- specific regions from NCBI database sequences. It detects over 12,000 species, including archaea, bacteria, fungi, protozoa, and viruses. For RNA samples, a reverse transcription reaction was performed with Superscript VILO per the guidance in the Axiom Microbiome Array User Guide. cDNA derived from the samples were used as a substrate for the Axiom whole genome amplification. No DNase treatment was employed on the RNA samples, therefore any DNA from the total nucleic acid preparations will be carried over in the whole genome amplification. The array was hybridized, washed and scanned on the GeneTitan Multi-Channel instrument in an automated fashion according to manufacturer’s instructions (Thermo Fisher, Waltham, MA). The 96-well plates were used to run the various clinical and spiked samples to evaluate the array’s sensitivity and applicability in clinical samples, as reported in Thissen et al. (Axiom Microbiome Array, the next generation microarray for high-throughput pathogen and microbiome analysis. PLoS ONE.2019). PCR amplification of the V3-V4 hypervariable region of the 16S rRNA gene. Library preparation was performed according to the standard instructions of the 16S Metagenomic Sequencing Library Preparation protocol (IlluminaTM, Inc., San Diego, CA, United States). One hypervariable region of the bacterial 16S rRNA gene (the V3-V4 region) was amplified using aliquots of the isolated DNA from each sample. The V3–V4 region of 16S rRNA gene was amplified in each sample by targeting the V3-V4 hypervariable region using the ^{Active 106822693} 22 069269.0650 following primers “forward” (TACGGGAGGCAGCAG) (SEQ ID NO: 1) and “reverse” (CCAGGGTATCTAATCC) (SEQ ID NO: 2). The resulting amplicons (456 bp) were subsequently subjected to high-throughput sequencing using the Illumina MiSeq platform. All low quality (<Q20) terminal bases were removed using Trimmomatic (v0.35), thus retaining the high quality reads only. All sequencing results after quality control, which are used in the project along with the metadata, have been submitted to Sequence Read Archive (SRA) NCBI database (accession number PRJNA554535). Microarray data analysis Microarray data were analyzed using the MiDAS software (Axiom Microbial Detection Analysis Software) (Thermo Fisher) which is based on the Composite Likelihood Maximization Method (CLiMax) algorithm developed at LLNL. Axiom MiDAS performs single-sample analysis of CEL files from Axiom Microbiome Arrays and automatically generates a comprehensive analysis summary in a simple-to-use software package. Probes with signal intensity above the 99th percentile of the random control probe intensities and with more than 20% of target-specific probes detected were considered positive. MiDAS uses initial and conditional scores to determine the likelihood of the target presence. The initial score is the log likelihood ratio for the target being present in the sample if no other targets are present, versus no targets being present in the sample. This value gives information on what the maximum possible contribution of that target is to the holistic model of the sample, based on the probes observed when interrogating a sample with the Axiom Microbiome Array. The conditional score gives an indicator of the actual contribution of each target to the model of the sample; it is the log likelihood for a model including the target vs for a model without the target. As the conditional score takes into account the presence of other targets, it can be lower than the initial score for a given target if there are probes in common between targets. 16S data analysis The filtered high-quality reads were stitched by using FLASH (v1.2.11). Script multiple_join_ paired_ends.py of QIIME (1.8.0) was used to assemble the 16S rRNA amplicons. Moreover, mismatched barcodes and sequences with length less than the threshold (200 bases), were removed. Chimeric sequences were removed using UCHIME (v4.2) providing valid tags (a high-quality sequence) for downstream microbial diversity analysis. These quality-filtered reads were clustered into operational taxonomic units ^{Active 106822693} 23 069269.0650 (OTUs; 97% identity) using de novo OTU picking and taxonomic assignment by implementing VSEARCH (v2.4.2) against Silva (v123), and Greengenes (gg13.8) reference databases utilizing QIIME script (pick_de_novo_ otus.py). The representative sequences were classified and annotated by the Naive Bayesian classification algorithm of RDP classifier (v2.2) as reported in Ahmad et al. (Analysis of gut microbiota of obese individuals with type 2 diabetes and healthy individuals; PLoS ONE.2019). Results The main goal of this study was to compare the gut microbiota of healthy cats and cats with feline atopic skin syndrome (FASS), in order to establish if the loss of diversity associated with atopic status in human and dogs was also present in cats; and, if applicable, to identify significant gut microbiota variations between the two groups, i.e., healthy vs. atopic/allergic or FASS. These two final groups (healthy vs. atopic/allergic or FASS) identified for the study are reported hereafter. Table 1: Patient characteristic analysis Table 1 reports the main characteristics from the two groups. No strong differences were observed, with an exception for neutered, when only 50% of cats were neutered from the control group. This ratio imbalance was correlated with healthy cat recruitments when neutering (Deusch et al.; A Longitudinal Study of the Feline Faecal Microbiome Identifies Changes into Early Adulthood Irrespective of Sexual Development; ^{Active 106822693} 24 069269.0650 PLOS ONE; 2015) had been previously demonstrated that feline gut microbiota is quite stable since 9 months of age (the youngest in the study was 9 months old). Also, it had been demonstrated that neither gender, neutered nor age when neutered impact gut microbiota. Yet, no statistical difference was noticed in bacterial proportions between neutered and unspayed cats. Accordingly, it was found that the two groups were comparable for further studies. Based on statistical analysis of the microarray assay, it was found that among the 30 most frequently identified bacterial strains, the prevalence of Helicobacter canis and Bacteroides vulgatus varied significantly between the two groups (healthy vs. allergic). Table 2: modulation of two species in Healthy vs. FASS groups It was found that is Helicobacter canis is not present in 60% of healthy cats and present in 14% of FASS (unadjusted p-value: 0.038= statistically significant). It was found that Bacteroides vulgatus is not present in 50% of healthy cats and present in nearly 100% of FASS (unadjusted p-value: 0.026= statistically significant). * * * Although the presently disclosed subject matter and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the presently disclosed subject matter as defined by the appended claims. Moreover, the scope of the present application is not intended to be limited to the particular embodiments of the process, machine, manufacture, and composition of matter, means, methods and steps described in the specification. As one of ordinary skill in the art will readily appreciate from the disclosure of the presently disclosed subject matter, processes, machines, manufacture, compositions of matter, means, methods, or steps, presently existing or later to be developed that perform substantially the same function or achieve substantially the same result as the corresponding embodiments described herein can be utilized according to the presently disclosed subject matter. Accordingly, the appended claims are intended to include within their scope such ^{Active 106822693} 25 069269.0650 processes, machines, manufacture, compositions of matter, means, methods, or steps. Patents, patent applications, publications, product descriptions and protocols are cited throughout this application the disclosures of which are incorporated herein by reference in their entireties for all purposes. ^{Active 106822693} 26